Yeast-based pharmacogenomics: An IFOM/IEO project to optimize the objectives of Phase I trials

被引：0
|
作者：
Spitaleri, Gianluca
Ferrari, Elisa
Foiani, Marco
Toffalorio, Francesca
Delmonte, Angelo
de Pas, Tommaso M.
Noberasco, Cristina
Catania, Chiara
de Braud, Filippo
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-2193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2193
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Bayesian dose finding in phase I clinical trials based on a new statistical framework
    Ji, Y.
    Li, Y.
    Yin, G.
    [J]. STATISTICA SINICA, 2007, 17 (02) : 531 - 547
  • [22] Evaluation of the cohort size in phase I dose escalation trials based on laboratory data
    Buöen, C
    Holm, S
    Thomsen, MS
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05): : 470 - 476
  • [23] Dose-finding in phase I clinical trials based on toxicity probability intervals
    Ji, Yuan
    Li, Yisheng
    Bekele, B. Nebiyou
    [J]. CLINICAL TRIALS, 2007, 4 (03) : 235 - 244
  • [24] A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer
    Madan, Ravi Amrit
    Singh, Nishith K.
    Gramza, Ann Wild
    Fojo, Antonio Tito
    Heery, Christopher Ryan
    Kim, Joseph W.
    McMahon, Sheri
    Rauckhorst, Myrna
    King, Thomas H.
    Apelian, David
    Schlom, Jeffrey
    Gulley, James L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine
    Kimmelman, Jonathan
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (12) : 719 - 720
  • [26] Systematic Review of Phase-I/II Trials Enrolling Refractory and Recurrent Ewing Sarcoma: Actual Knowledge and Future Directions to Optimize the Research
    Felix, A.
    Berlanga, P.
    Le Deley, M. C.
    Gaspar, N.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 : S293 - S294
  • [27] Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research
    Felix, Arthur
    Berlanga, Pablo
    Toulmonde, Maud
    Landman-Parker, Judith
    Dumont, Sarah
    Vassal, Gilles
    Le Deley, Marie-Cecile
    Gaspar, Nathalie
    [J]. CANCER MEDICINE, 2021, 10 (05): : 1589 - 1604
  • [28] Use of inflammation-based scores to optimize the selection of patients with advanced cancer considered for early-phase clinical trials
    Pinato, David James
    Stavraka, Chara
    O'Cathail, Sean Micheal
    Seckl, Michael
    Blagden, Sarah Patricia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib
    El-Madani, Mevidette
    Colomban, Olivier
    Tod, Michel
    Maillet, Denis
    Peron, Julien
    Rodriguez-Lafrasse, Claire
    Badary, Osama A.
    Valette, Pierre-Jean
    Lefort, Thibaud
    Cassier, Philippe
    El-Shenawy, Siham M.
    EL-Demerdash, Ebtehal
    Hommel-Fontaine, Juliette
    Guitton, Jerome
    Gagnieu, Marie-Claude
    Ibrahim, Bassan M. M.
    Barrois, Catherine
    Freyer, Gilles
    You, Benoit
    [J]. FUTURE ONCOLOGY, 2017, 13 (08) : 679 - 693
  • [30] Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity
    Thall, PF
    Lee, SJ
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (03) : 251 - 261
12345